4D Molecular Therapeutics, Inc. Common Stock
FDMT4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company focused on developing targeted gene therapies for various genetic and acquired diseases. Utilizing its proprietary vector platform, 4DMT aims to deliver precise and durable treatments through innovative vector design and delivery methods. The company emphasizes leveraging advanced genetic engineering technologies to create therapies with enhanced specificity and reduced immunogenicity.
Company News
4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash posit...
DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Pha...
4D Molecular Therapeutics (4DMT) announced that management will present at three major investor conferences in March 2026: TD Cowen Health Care Conference (March 3), Leerink Global Healthcare Conference (March 10), and Barclays Global Healthcare Conference (March 12). The company is advancing late-stage biotech therapeutics including 4D-150 for r...
4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.
4D Molecular Therapeutics partnered with Otsuka Pharmaceutical to develop and commercialize 4D-150, a potential transformative therapy for retinal vascular diseases in the Asia-Pacific region, receiving $85 million upfront and potential milestone payments up to $336 million.
